Latest On-Demand Webinars & Online Events

In this webinar, data integrity expert Bob McDowall explains how to ensure the integrity and compliance of reported data, from sampling to reporting.

Watch this webinar to learn how the evaluation of binding affinities can support viral research and assist in the identification of novel drugs.

Recent observations by Prof. Gorochov’s team at the CIMI Research Centre suggest that there are at least two distinct types of cytokine signatures induced by SARS-CoV-2 infection.

With the development of long-read sequencing technology and improved computational methods, it is now possible for small teams of researchers to create reference-quality genome assemblies which will lead to a better understanding of the full spectrum of human genetic variation.

Research focused on SARS-CoV-2 has become a primary focus in genomic and molecular biology fields. The availability of accurate, efficient, and consistent analytical tools, including new methods for screening and studying virus-host interactions, is critical.

Gene therapy is rapidly gaining importance as a critical treatment modality in the prevention or cure of a wide range of diseases. However, getting a product to market for commercial use does not come without its challenges.

As current events have demonstrated, infectious diseases represent a significant global concern. The ability for a novel infectious disease to appear and spread worldwide is greater now than at any time in our history.

Surveillance analysis of potentially pathogenic microbes found in shared public resources is an important component of research aimed at understanding, preparing for, and protecting communities from potential widespread infection and transmission of infectious diseases.

In this webinar, Dr. Kristin G. Anderson, Research Associate from the Greenberg lab at the Fred Hutchinson Cancer Research Center, discusses engineering T cells to improve survival in the immunosuppressive tumor microenvironment.

Vanderbilt University Medical Center researchers Robert Carnahan and Pavlo Gilchuk are attempting to compress the timeline for therapeutic antibody development, by integrating a series of advances in single-cell messenger RNA sequence analysis, bioinformatics, synthetic biology and high-throughput functional analysis.